NASC (Nascent Pharma Holdings) EBIT per Share: $-0.24 (TTM As of Sep. 2024)

What is Nascent Pharma Holdings EBIT per Share?

Nascent Pharma Holdings NASC -9.65% 12 EBIT per Share is $-0.24 as of Sep. 2024. GuruFocus rates NASC with a GF Score™ of 12/100.

Nascent Pharma Holdings's EBIT per Share for the three months ended in Sep. 2024 was $-0.04. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.24.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Nascent Pharma Holdings's EBIT per Share or its related term are showing as below:

NASC's 3-Year EBIT Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 7.65
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Nascent Pharma Holdings's EBIT for the three months ended in Sep. 2024 was $-2.83 Mil.

Nascent Pharma Holdings (OTCPK:NASC) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Nascent Pharma Holdings EBIT per Share Related Terms

Nascent Pharma Holdings EBIT per Share Historical Data

* Premium members only.

The historical data trend for Nascent Pharma Holdings's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nascent Pharma Holdings EBIT per Share Chart

Nascent Pharma Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-32.91

-33.65

-7.50

-3.93

-0.57

Nascent Pharma Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial															-0.31	-0.02	-0.15	-0.03	-0.04

12GF Score

Nascent Pharma Holdings Inc NASC

EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Nascent Pharma Holdings EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Nascent Pharma Holdings's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-7.217	/	12.590
=	-0.57

Nascent Pharma Holdings's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.832	/	65.436
=	-0.04

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.24

Frequently Asked Questions Learn more about EBIT per Share →

What does a EBIT per Share of $-0.24 mean?

Nascent Pharma Holdings (NASC) has a EBIT per Share of $-0.24 as of Sep. 2024. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Nascent Pharma Holdings and its competitors.

Is Nascent Pharma Holdings' EBIT per Share too high?

Nascent Pharma Holdings' current EBIT per Share is $-0.24. Overall, Nascent Pharma Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.

How does Nascent Pharma Holdings' EBIT per Share compare to ALID and CPMD?

Nascent Pharma Holdings' EBIT per Share of $-0.24 can be compared against companies in the Drug Manufacturers industry. The industry median EBIT per Share is 7.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT per Share for a Drug Manufacturers company?

The median EBIT per Share among Drug Manufacturers companies is 7.65, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT per Share mean?

A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Nascent Pharma Holdings and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nascent Pharma Holdings's current EBIT per Share is $-0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Nascent Pharma Holdings stock overvalued right now?

Nascent Pharma Holdings (NASC) has a current EBIT per Share of $-0.24. The current EBIT per Share is $-0.24. Nascent Pharma Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT per Share calculated?

EBIT per Share is calculated from a company's financial statements. For Nascent Pharma Holdings (NASC), the current EBIT per Share is $-0.24 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nascent Pharma Holdings Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies ALID CPMD PLSH KAYS PTPI CBDY STEK NXEN UPC PRFX ZTS XTER:MRK TSE:4502 NSE:SUNPHARMA XSWX:GALD LSE:HLN HKSE:03692 XSWX:SDZ XTAE:TEVA SHSE:688506

Address 44 East End Avenue, Hicksville, NY, USA, 11801

Website https://nascentpharmaholdings.com

Nascent Pharma Holdings Inc has acquired a Subsidiary engaged in enforcing and commercializing the patents held by Nascent. The acquired patents cover liquid formulations of cannabis. The patents relate to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance for incorporation into a medicament and for use in pharmaceutical formulations, in particular comprising cannabinoids obtained from cannabis. Patented uses include using the liquid formulations to alleviate numerous debilitating conditions, including cancer, irritable bowel syndrome, chronic pain, post-traumatic stress disorder, anxiety, sleep disorders, and opioid dependencies.

12GF Score

Get the complete analysis for NASC

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01

Price

View NASC Analysis

See EBIT per Share data for all stocks →